Related Experiment Video

Updated: Feb 23, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.6K

Exploiting poly(I:C) to induce cancer cell apoptosis

Francesca Bianchi1,2, Samantha Pretto2, Elda Tagliabue1

  • 1a Fondazione IRCCS Istituto Nazionale dei Tumori , Department of Research, Epidemiologia e Medicina Molecolare , via Amadeo 42, Milan , Italy.

Cancer Biology & Therapy
|September 8, 2017
PubMed

Insights

Toll-like receptor 3 (TLR3) agonist poly(I:C) directly induces apoptosis in cancer cells. Understanding TLR3 signaling and its regulators can enhance poly(I:C) cancer therapy by promoting cancer cell death.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • Toll-like receptors (TLR3) are key components of the innate immune system, primarily expressed on immune cells.
  • TLR3 agonists, such as poly(I:C), mimic pathogen infection to activate immune responses and are investigated for anti-cancer therapy.
  • Poly(I:C) has demonstrated direct cancer cell apoptosis induction in experimental models.

Purpose of the Study:

  • To review current knowledge on poly(I:C)-induced apoptosis mechanisms in cancer cells.
  • To identify positive and negative regulators of TLR3-mediated apoptosis.
  • To propose strategies for enhancing poly(I:C)-induced apoptosis in cancer treatment.

Main Methods:

  • Literature review of experimental evidence on TLR3 signaling and poly(I:C) effects.
  • Analysis of mechanisms underlying poly(I:C)-induced apoptosis in cancer cells.
  • Identification and discussion of regulatory factors influencing TLR3-mediated apoptosis.

Main Results:

  • Poly(I:C) induces apoptosis in TLR3-expressing cancer cells, acting as an additional therapeutic arm beyond immune activation.
  • Both positive and negative regulators of TLR3-mediated apoptosis have been identified.
  • Strategies to promote poly(I:C)-induced apoptosis are being explored.

Conclusions:

  • Poly(I:C) offers a dual mechanism for cancer treatment: immune system activation and direct cancer cell apoptosis.
  • Further research into TLR3 signaling is crucial to fully exploit poly(I:C)-induced apoptosis.
  • Considering negative regulators of apoptosis is essential for successful clinical trials with TLR3 agonists.
Keywords:
TLR agonistToll-like receptor 3 (TLR3)apoptosiscancerdouble-stranded RNA (dsRNA)immune cellspoly(I:C)

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.6K

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
9.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.7K